Stay updated on Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial

Sign up to get notified when there's something new on the Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    6%
    Check dated 2025-05-29T05:57:25.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    32 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.3%
    Check dated 2025-04-30T13:57:32.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The webpage has removed a date reference of January 22, 2025, and added a new date reference of April 17, 2025.
    Difference
    0.7%
    Check dated 2025-04-23T08:38:30.000Z thumbnail image
  6. Check
    46 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.4 to v2.15.0, indicating a significant revision. Additionally, a phrase has been removed and replaced with a similar one, but the core content remains unchanged.
    Difference
    1.0%
    Check dated 2025-04-16T02:15:11.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    The web page has updated its version from v2.14.3 to v2.14.4, and the date has changed from March 25, 2025, to January 22, 2025.
    Difference
    1.0%
    Check dated 2025-04-08T23:50:00.000Z thumbnail image
  8. Check
    96 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    5%
    Check dated 2025-02-24T19:10:42.000Z thumbnail image

Stay in the know with updates to Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Durvalumab ± Tremelimumab Combo in Untreated ES-SCLC Clinical Trial page.